MaaT Pharma SA (MAAT.PA)
EUR 5.86
(1.38%)
EUR 5.86
(1.38%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.65 Million EUR | -28.14% |
| 2022 | 1.09 Million EUR | 35.36% |
| 2021 | 806 Thousand EUR | 591.46% |
| 2020 | -164 Thousand EUR | -2030.98% |
| 2019 | -7696.00 EUR | -100.95% |
| 2018 | 813 Thousand EUR | 123.97% |
| 2017 | -3.39 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 592 Thousand EUR | 362.5% |
| 2024 Q2 | 592 Thousand EUR | 145.35% |
| 2023 Q1 | 547 Thousand EUR | 22.37% |
| 2023 Q2 | 894 Thousand EUR | 63.44% |
| 2023 FY | 784 Thousand EUR | -28.14% |
| 2023 Q3 | 128 Thousand EUR | -85.68% |
| 2023 Q4 | 128 Thousand EUR | 0.0% |
| 2022 FY | 1.09 Million EUR | 35.36% |
| 2022 Q4 | 447 Thousand EUR | 144.26% |
| 2022 Q3 | 183 Thousand EUR | -22.46% |
| 2022 Q2 | 236 Thousand EUR | 11.85% |
| 2022 Q1 | 211 Thousand EUR | -11.34% |
| 2021 Q4 | 238 Thousand EUR | 67.61% |
| 2021 FY | 806 Thousand EUR | 591.46% |
| 2021 Q3 | 142 Thousand EUR | -61.78% |
| 2021 Q2 | 371.5 Thousand EUR | 107.54% |
| 2021 Q1 | 179 Thousand EUR | 126.6% |
| 2020 FY | -164 Thousand EUR | -2030.98% |
| 2020 Q3 | -583.5 Thousand EUR | -214.64% |
| 2020 Q2 | 509 Thousand EUR | -10.39% |
| 2020 Q1 | 568 Thousand EUR | 0.0% |
| 2020 Q4 | -673 Thousand EUR | -15.34% |
| 2019 FY | -7696.00 EUR | -100.95% |
| 2018 FY | 813 Thousand EUR | 123.97% |
| 2017 FY | -3.39 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -167.799% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 57.716% |
| Adocia SA | 1.38 Million EUR | -19.495% |
| Aelis Farma SA | 12.35 Million EUR | 86.608% |
| Biophytis S.A. | -803 Thousand EUR | 306.102% |
| Advicenne S.A. | 1.42 Million EUR | -16.059% |
| genOway Société anonyme | 20.1 Million EUR | 91.766% |
| IntegraGen SA | 5.01 Million EUR | 67.021% |
| Medesis Pharma S.A. | -2.66 Million EUR | 162.107% |
| Neovacs S.A. | 29.31 Thousand EUR | -5545.767% |
| NFL Biosciences SA | -56.06 Thousand EUR | 3051.983% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 23.128% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 216.608% |
| Sensorion SA | 3.78 Million EUR | 56.308% |
| Theranexus Société Anonyme | -4.63 Million EUR | 135.678% |
| TME Pharma N.V. | -127 Thousand EUR | 1403.15% |
| Valbiotis SA | 2.66 Million EUR | 37.969% |
| TheraVet SA | -530.79 Thousand EUR | 411.796% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -30.624% |
| DBV Technologies S.A. | 4.15 Million EUR | 60.212% |
| Genfit S.A. | 28.22 Million EUR | 94.136% |
| GeNeuro SA | -293.8 Thousand EUR | 663.308% |
| Innate Pharma S.A. | -4.12 Million EUR | 140.16% |
| Inventiva S.A. | 17.5 Million EUR | 90.543% |
| MedinCell S.A. | 9.28 Million EUR | 82.181% |
| Nanobiotix S.A. | 36.2 Million EUR | 95.429% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 25.685% |
| Poxel S.A. | 1000.00 EUR | -165400.0% |
| GenSight Biologics S.A. | 3 Million EUR | 44.833% |
| Transgene SA | -28.4 Million EUR | 105.827% |
| Valneva SE | 52.83 Million EUR | 96.868% |